Relief Therapeutics private placement of CHF 15 million. The advisors

H.C. Wainwright acted as sole placement agent in connection to the private placement of 71,428,572 shares in Relief Therapeutics Holding, a Swiss biopharmaceutical company listed at SIX Swiss Exchange, at a price of CHF 0.21 per share. 

The aggregate gross proceeds from the private placement are expected to be approximately CHF 15 million, before deducting the placement agent fees and offering expenses payable by Relief. The private placement offering is expected to close on or about July 28, 2021, subject to the satisfaction of customary closing conditions.  

Relief plans to use the net proceeds from the private placement to acquire additional assets to expand and diversify its drug pipeline, meet its obligations to pay potential milestone payments and for general corporate purposes.  

The advisors

 Vischer advised Relief on the Swiss legal aspects of this transaction. The Vischer team, led by partner Robert Bernet (corporate / m&a, pictured) included Peter Kühn (counsel, corporate / m&a) and Christian Schneiter (senior associate, banking & finance).

Pestalozzi advised H.C. Wainwright with regard to all Swiss legal aspects of the transaction. The Pestalozzi team was led by partner Christian Leuenberger (capital markets, corporate/m&a, pictured left), Severin Roelli (partner – corporate/m&a), Manu Ferro (associate –banking & finance).